| Active substance | Elexacaftor/Tezacaftor/Ivacaftor and Ivacaftor |
| Holder | Parexel International on behalf of Vertex Pharmaceuticals Incorporated |
| Status | Running |
| Indication | for Patients 2 Through 5 Years of Age With Cystic Fibrosis Who Have At Least One F508del Mutation in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Gene |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 18/09/2023 |